Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) insider transactions

In the twelve months to 10 November 2026, executives and directors of Johnson & Johnson reported 28 open-market sales of 609,222 shares ($150.7m) and 1 open-market purchase of 1,250 shares ($257,688), by 11 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Johnson & Johnson shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
2 September 2026Schmid TimothyEVP, WW Chair, MedTechOption exercise+11,070$131.9436,517Form 4
2 September 2026Schmid TimothyEVP, WW Chair, MedTechOpen-market sale−11,070$274.7425,447Form 4
2 September 2026Schmid TimothyEVP, WW Chair, MedTechOption exercise+22,527$151.4147,974Form 4
2 September 2026Schmid TimothyEVP, WW Chair, MedTechOpen-market sale−22,527$274.7425,447Form 4
17 August 2026Taubert Jennifer LEVP, WWC. Innovative MedicineOption exercise+15,000$115.67209,451Form 4
17 August 2026Taubert Jennifer LEVP, WWC. Innovative MedicineOpen-market sale−15,000$263.36194,451Form 4
13 August 2026Duato JoaquinCEO and Chairman of the BoardOption exercise+123,291$115.67399,258Form 4
13 August 2026Duato JoaquinCEO and Chairman of the BoardOpen-market sale−20,976$262.00378,282Form 4
13 August 2026Duato JoaquinCEO and Chairman of the BoardOpen-market sale−102,315$261.00275,967Form 4
6 August 2026Forminard ElizabethEVP, Chief Legal OfficerOption exercise+9,344$131.9432,912Form 4
6 August 2026Forminard ElizabethEVP, Chief Legal OfficerOpen-market sale−9,344$257.7623,568Form 4
6 August 2026Forminard ElizabethEVP, Chief Legal OfficerOpen-market sale−6,574$255.9316,994Form 4
5 August 2026Duato JoaquinCEO and Chairman of the BoardOpen-market sale−41,957$258.06282,490Form 4
5 August 2026Duato JoaquinCEO and Chairman of the BoardOpen-market sale−6,523$258.74275,967Form 4
20 July 2026Broadhurst VanessaEVP, Global Corp AffairsOption exercise+11,129$129.5134,132Form 4
20 July 2026Broadhurst VanessaEVP, Global Corp AffairsOption exercise+11,925$131.9446,057Form 4
20 July 2026Broadhurst VanessaEVP, Global Corp AffairsOpen-market sale−23,054$251.2723,003Form 4
11 June 2026Wengel Kathryn EEVP, Chief TO and Risk OfficerOption exercise+10,000$115.67124,288Form 4
11 June 2026Wengel Kathryn EEVP, Chief TO and Risk OfficerOpen-market sale−10,000$241.15114,288Form 4
1 May 2026Reed John CEVP, Innovative Medicine, R&DOption exercise+25,255—35,913Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Johnson & Johnson page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.